- Omega Diagnostics said it expected to post a full-year loss amid a fall in sales.

Adjusted pre-tax losses for the year through March would amount to £0.3m, narrowing from £0.7m of losses on-year, the company said.

Revenue was seen falling 28% to £9.8m, partly due to the sale or closure of German and infectious disease businesses.

With the impact of those asset sales stripped out, revenue would rise 3.0% to £9.76m.

'We have made significant progress in the last 12 months to streamline our business and to focus on those areas that can deliver the most shareholder value,' chief executive Colin King said.

'Our food intolerance division has performed well and is positioned for further growth.'

'I am also very pleased with the progress that the company has made over the last year in completing the development of our Visitect CD4 tests and assuring these tests meet the regulatory requirements in multiple countries.'

'This will enable their purchase and use, benefiting the hundreds of thousands of people currently living with HIV, especially those living in resource limited settings.'

Story provided by